Your session is about to expire
← Back to Search
DEC-C Pre-emptive Therapy for Myelodysplastic Syndrome
Study Summary
This trial is testing whether a treatment of decitabine and cedazaridine (DEC-C) can decrease the risk of progression in post-transplant myelodysplastic syndromes (MDS) patients with persistent mutations (molecular MRD). To detect molecular MRD, the investigators will use MyeloSeq-HD sequencing at Day 30 in post-transplant MDS patients. The investigators will treat patients with detectable molecular MRD with DEC-C to determine if pre-emptive, MRD-guided therapy with DEC-C decreases relapse rates and improves progression-free survival.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- Group 1: Phase I Dose Level 2: DEC-C
- Group 2: Phase II MRD Positive: DEC-C
- Group 3: Phase I Dose Level 1: DEC-C
- Group 4: Phase II MRD Negative: Observation Arm
Frequently Asked Questions
What is the principal application of DEC-C?
"DEC-C is routinely employed to address intermediate ipss risk category 2. Additionally, this drug is often prescribed for high risk ipss, refractory anemias and anaemia cases."
How many participants are included in this medical research study?
"Yes, the information posted on clinicaltrials.gov attests that this trial is actively recruiting; it was first published on May 12th 2022 and most recently updated on October 10th 2022. 126 participants are needed to be enrolled from a single medical facility."
Are there any available openings in this trial for participants?
"Affirmative. Information available on clinicaltrials.gov specifies that this medical trial, which was originally posted on May 12th 2022, is actively searching for participants. A total of 126 patients are expected to be recruited from 1 site."
Have any scholarly works investigated the effects of DEC-C?
"Presently, 104 experiments are underway studying DEC-C. Sixteen of these live clinical trials have moved on to Phase 3. Although most studies for this treatment take place in Philadelphia Pennsylvania, there are 1491 medical sites conducting research related to DEC-C."
Share this study with friends
Copy Link
Messenger